Therakos is granted MDR approval in Europe to treat immune-related adverse events in patients who are insufficiently responding to corticosteroids.

Summary

DUBLIN, 23 October 2026 — Therakos Development Limited, a global leader in immunomodulatory therapy, is committed to providing extracorporeal photopheresis (ECP) directly to the patient.